ulates a broad inflammatory response in these cells such as heightened expression of proinflammatory cytokines, adhesion molecules, matrix degrading enzymes, and procoagulants-all probable participants in atherogenesis and lesion complication. 6 Indeed, we and others previously demonstrated that atherosclerosis-prone mice such as low-density lipoprotein receptor (LDLR)-or apolipoprotein E-deficient animals that lack CD40L genetically or those treated with neutralizing anti-CD40L antibodies develop markedly reduced levels of atherosclerosis on high-cholesterol diets. 7, 8 Similarly, atherosclerotic lesions in such animals display features associated with plaque stability (ie, reduced macrophage and lipid content as well as increased collagen con-tent). Indeed, CD40L inhibition even retards progression of preexisting atherosclerotic lesions in such animals. 9, 10 Finally, soluble CD40L (sCD40L), the 18-kD soluble form predominantly released from platelets on platelet activation may identify first or recurrent cardiovascular events, which further supports the pathogenic role of CD40L. [11] [12] [13] The present study originally aimed to identify the contribution of the receptor CD40 to atherogenesis in mice. Unexpectedly, the results revealed that modulation of murine atherosclerosis by CD40L does not depend on its classic receptor, CD40. Therefore, we sought a potential alternative receptor for CD40L. CD40L binds to the platelet integrin glycoprotein (GP) IIb/IIIa (␣ IIb␤3 , CD41/CD61) and induces outside-in signaling and thereby platelet activation. 14, 15 The major ligand of GP IIb/IIIa is the plasma protein fibrinogen. However, fibrinogen can also bind another integrin receptor, Mac-1 (␣ M␤2 , CD11b/CD18), expressed abundantly on monocytes/macrophages, a cell type of pivotal importance in atherogenesis. Mac-1 function is strongly and rapidly regulated via conformational changes of the receptor, which is also true for GP IIb/IIIa. Mac-1 is a highly promiscuous receptor that interacts with ligands such as C3bi, 16 intracellular adhesion molecule-1, 17 fibrinogen, 18 vitronectin, 19 factor Xa, 20, 21 heparin, 22, 23 GP Ib␣, 24, 25 JAM-3, 26 and lipoprotein (a). 27 Based on these interactions, Mac-1 participates in processes important in atherosclerosis such as inflammation, immune response, and coagulation. 28 -31 Therefore, we further tested the hypothesis that CD40L interacts with the monocyte/macrophage integrin Mac-1.
Methods
A detailed description of all methods is accessible in the online Data Supplement. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results

CD40-Deficiency Does Not Attenuate the Development of Atherosclerotic Lesions in Mice
We and others previously demonstrated that genetic deficiency of CD40L or treatment with neutralizing anti-CD40L antibodies slows both onset and progression of atherosclerotic lesions in LDLR Ϫ/Ϫ mice. 7, 8 To explore the contribution of CD40 to atherogenesis, CD40 Ϫ/Ϫ /LDLR Ϫ/Ϫ and LDLR Ϫ/Ϫ mice consumed a high-cholesterol diet for 8 and 16 weeks. Total cholesterol and triglyceride levels did not differ statistically between the study groups (data not shown). Surprisingly, intimal lesion size of aortic arches was similar between CD40-deficient and control animals after 8 weeks (0.028Ϯ0.007 versus 0.037Ϯ0.007 mm 2 , PϭNS) ( Figure 1A ) and 16 weeks of consumption of the high-cholesterol diet (0.254Ϯ0.032 versus 0.282Ϯ0.036 mm 2 , PϭNS) ( Figure  1A ). Analysis of lesions in the aortic roots ( Figure 1B ) and thoracoabdominal aortas ( Figure 1C ) yielded similar results, which demonstrates that CD40 deficiency does not attenuate atherogenesis in these mice.
In agreement with our findings, the lesions of LDLR (Figure 1D ), which contrasted with our previous findings in CD40L-deficient and anti-CD40L antibody-treated mice. 7, 8 The differences in Oilred-O content between abdominal aortas and aortic arches may in part reflect different stages in plaque development potentially caused by distinct flow and shear stress profiles. 32, 33 sCD40L Binds to Mac-1 Four different experimental approaches tested the hypothesis that CD40L interacts directly with Mac-1: (1) Flow cytometry evaluated the binding of a flag-tagged recombinant sCD40L to nonstimulated and paramethoxyamphetamine (PMA)-stimulated human monocytes in the presence or absence of anti-Mac-1 antibody. sCD40L bound to monocytes, in particular to PMA-stimulated monocytes. An antiMac-1 antibody inhibited this binding ( Figure 2A) . (2) The binding of 125 I-labeled sCD40L to Chinese hamster ovary (CHO) cells that expressed either nonactivated (CHO-WtMac-1) or activated Mac-1 (CHO-Del-Mac-1) further supported the notion of a direct interaction between sCD40L and Mac-1. Similar to the results obtained with flow cytometry in monocytes, the activated Mac-1 bound strongly sCD40L, whereas the nonactivated Mac-1 bound only weakly ( Figure  2B ). In both cases, blocking anti-Mac-1 monoclonal antibody strongly reduced sCD40L binding ( Figure 2B ). (3) A blocking anti-Mac-1 antibody inhibited binding of radiolabeled sCD40L on activated monocytes, whereas control antibodies such as anti-P-selectin and anti-GP IIb/IIIa antibodies did not inhibit sCD40L binding ( Figure 2C ). (4) Finally, direct binding of sCD40L was investigated with sCD40L as bait to precipitate its binding partner. Interestingly, sCD40L precipitated activated Mac-1 expressed on CHO cells, but not nonactivated Mac-1 ( Figure 2D ). This observation agrees with the preferred binding of sCD40L to activated Mac-1 (Figure 2A through 2C) . Overall, several lines of evidence support the concept of direct binding of CD40L to the integrin receptor Mac-1.
CD40L Mediates Cell Adhesion by Interaction With Mac-1
Static adhesion assays tested the functional relevance of the interaction between CD40L and Mac-1 for monocyte adhesion (nՆ6 each). Plates coated with sCD40L showed significantly greater monocyte adhesion than those coated only with agarose (106Ϯ3% versus 10Ϯ2%, PϽ0.05) ( Figure 3A) . Stimulation with PMA further enhanced CD40L-mediated adhesion (to 134Ϯ16, PϽ0.05) ( Figure 3A) . Preincubation with anti-Mac-1 antibody (100 g/mL) limited both stimulated and nonstimulated leukocyte adhesion to sCD40L-coated plates (to 28Ϯ7 and 5Ϯ2%, PϽ0.008, respectively) ( Figure 3A) , which demonstrated that CD40L-Mac-1 interaction mediates leukocyte adhesion. monocytes. CHO cells expressing the nonactivated Mac-1 (CHO-Wt-Mac-1), and even more so those that expressed activated Mac-1 (CHO-Del-Mac-1), displayed significantly enhanced adhesion compared with respective control CHO cells, an effect that again was reversed by an anti-Mac-1 antibody ( Figure 3B ). PMA stimulation in these recombinant cells did not increase the affinity of the Mac-1 receptors, but increased adhesion strength in general via stimulation of cytoskeletal rearrangements. Nevertheless, an anti-Mac-1 antibody specifically inhibited adhesion (data not shown). To validate that our observations in human cells also apply to mice, we isolated monocytes from a pool of 16 wild-type mice, and allowed them to interact with sCD40L-coated plates in the presence and absence of anti-Mac-1 antibody. Similar to our previous results, interaction of murine monocytes with sCD40L proved to be dependent on Mac-1 (Data Supplement Figure I ).
CD40L-Mac-1 Interaction Enhances Monocyte Migration In Vitro
To test the hypothesis that CD40L not only binds to Mac-1 on monocytes, which results in the enhanced monocyte adhesion demonstrated above, but also promotes monocyte locomotion, we performed migration assays in a modified Boyden chamber. Soluble CD40L significantly enhanced monocyte migration compared with controls (28Ϯ13% versus 9Ϯ7%, PϽ0.05) ( Figure 3C ). Mac-1 mediates this effect, because pretreatment of monocytes with antiMac-1 antibody inhibited migration completely (to 2Ϯ0.7%, PϽ0.05) ( Figure 3C ).
CD40L-Mac-1 Interaction Enhances Secretion of Myeloperoxidase by Monocytes
To test the hypothesis that CD40L also promotes the release of prooxidant mediators from monocytes in a Mac-1-depen- dent fashion, we assayed supernatants from static adhesion assays for myeloperoxidase (MPO) protein. Supernatants from plates coated with sCD40L contained significantly more MPO than those coated only with agarose (66Ϯ12% versus 25Ϯ3%, PϽ0.05; data not shown). Stimulation of monocytes with PMA further enhanced MPO secretion on sCD40L-coated plates (to 136Ϯ11, PϽ0.05) ( Figure 3D ), and antiMac-1 (100 ng/mL) antibody significantly inhibited both nonstimulated and stimulated secretion of MPO (to 30Ϯ5% and 46Ϯ9%, PϽ0.008, respectively) ( Figure 3D ).
CD40L-Mac-1 Interactions Persist Under Flow Conditions
We further tested whether CD40L-Mac-1 interactions persist under flow conditions relevant to those in human vessels. Under venous flow conditions, significantly more monocytes adhered on sCD40L-coated plates both without stimulation and in particular after PMA stimulation with a maximum after 5 minutes. Monocyte adhesion attenuated but persisted under simulated arterial flow conditions ( Figure 4A and 4B) . Again, pretreatment of monocytes with anti-Mac-1 antibody abrogated monocyte adhesion in both cases ( Figure 4A and 4B), which corroborated the concept of direct CD40L-Mac-1 interaction that mediates leukocyte adhesion. The effects also persisted when arterial flow was applied from the beginning on, though overall adhesion fell markedly (data not shown).
CD40L Induces Leukocyte Migration In Vivo via Interaction With Mac-1
To test whether our in vitro observations extend to in vivo inflammation, we induced sterile peritonitis chemically in mice (nՆ3 per group). After intraperitoneal injection (4 hours) of 4% thioglycolate, peritoneal leukocyte counts were significantly lower in CD40L 6 , PϭNS) ( Figure 5A ). These data affirm that in contrast to CD40L-CD40 interactions, CD40L-Mac-1 participates pivotally in leukocyte recruitment in vivo. Additional experiments that involve injection of PBS or sCD40L (75 g/mouse) intraperitoneally also demonstrated increased monocyte accumulation in the peritoneal fluid (5.1Ϯ0.9ϫ10 6 versus 3.0Ϯ0.3ϫ10 6 , Pϭ0.08) ( Figure 5B ), an effect reversed by pretreatment with anti-Mac-1 (100 g/mouse) antibody (to 1.4Ϯ0.3ϫ10 6 , Pϭ0.02) ( Figure 5B ). Intraperitoneal injection of mock-transfected fibroblasts (WT-fibroblasts) or fibroblasts that overexpressed CD40L (CD40L-fibrobalsts) for 4 and 72 hours further corroborated these findings ( Figure 5C and 5D). 
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Inhibition of Mac-1 Attenuates Atherogenesis in Mice and Reduces Lesional Macrophage Accumulation
Because mechanisms that trigger peritoneal inflammation may be distinct from inflammatory processes that lead to atherogenesis, we tested whether Mac-1 modulates atherogenesis in vivo. Therefore LDLR Ϫ/Ϫ mice consumed a highcholesterol diet for 10 weeks and received either 75 g of anti-mouse Mac-1 antibody or carrier alone as control 3 times per week. Indeed, mice treated with anti-Mac-1 antibody developed smaller atherosclerotic lesions than respective controls ( Figure 6A ), which demonstrates a functional role of Mac-1 in atherogenesis. Immunohistochemical analysis of lesion composition demonstrated similar lipid content, but reduced macrophage accumulation in lesions of anti-Mac-1 treated animals, which suggests that Mac-1 promotes atherogenesis in vivo by increasing lesional macrophage invasion ( Figure 6B and 6C) .
Discussion
The present study made the surprising finding that CD40 does not contribute to CD40L-induced atherogenesis. Follow-up of this unexpected result led to the novel observation that CD40L interacts with the integrin Mac-1 and that these interactions can elicit monocyte adhesion and migration as well as MPO release in vitro and in vivo. These data uncover a novel mechanism of inflammatory signaling with implications for future treatment strategies that target CD40L.
Robust evidence implicates CD40L in the pathogenesis of atherosclerosis and its complications. 2, 6 Cells found in atheromata not only express both ligand and receptor, but the stimulation of endothelial cells, macrophages, and smooth muscle cells with CD40L triggers a broad proinflammatory response. 5,36 -39 In mice, genetic deficiency of CD40L and treatment with neutralizing antibodies that target CD40L decrease atherosclerotic lesion size, reduce preexisting disease, and also yield more fibrous plaques, a finding of potential clinical relevance. [7] [8] [9] [10] 40 In contrast to expectations, our data suggest that CD40 does not mediate the proatherogenic functions of CD40L. Indeed, LDLR Ϫ/Ϫ mice that lack CD40 developed atherosclerotic lesions similar in size to those of corresponding control animals, irrespective of vascular location (arch, root, or abdominal aorta).
Macrophage invasion into the intima represents a key step in atherogenesis. 3, 41 We previously demonstrated that CD40L-deficiency reduces lesion size and macrophage content of mouse atheromata. 8 In contrast, the present study demonstrates similar lesion size of and even enhanced macrophage content in lesions from CD40 Ϫ/Ϫ /LDLR Ϫ/Ϫ mice, which suggests that CD40L-induced monocyte accumulation in plaques does not require CD40. The increased Oil-red-O and macrophage content in lesions from LDLR Ϫ/Ϫ mice that lack CD40 may even reflect a counterregulatory mechanism. In light of these data and previous reports that describe interactions of CD40L with integrin family members, and in view the crucial role of Mac-1 in monocyte recruitment, we hypothesized that CD40L, soluble or membrane-bound, mediates some of its proatherogenic functions via interaction with the integrin Mac-1 on inflammatory cells.
Several lines of evidence establish a pivotal role for Mac-1 in monocyte adhesion to the endothelium, one of the initial steps of atherosclerotic lesion development. 28 -30,42 In contrast to other integrins such as LFA-1, recent work implicated Mac-1, particularly in the later, firmer adhesion under flow conditions. 43, 44 Furthermore, Mac-1 participates importantly in the transendothelial migration of monocytes that initiate a cascade of events that ultimately lead to plaque inflammation, growth, and destabilization. 3, 41 Rogers et al reported decreased intimal thickening after arterial balloon injury in rabbits after administration of Mac-1 antibodies. 45 Simon et al extended these results to Mac-1-deficient mice, and thus demonstrated the in vivo relevance of Mac-1 in the arterial response to injury. 46 Interestingly, Mac-1 binds to several other ligands apart from intracellular cell adhesion molecule-1, such as fibrinogen, lipoprotein (a), Thy-1 (CD90), receptor of advanced glycation end products, and vitronectin. 19, 27, [47] [48] [49] Notably, several of these ligands associate with leukocyte adhesion/transmigration as well as atherogenesis.
Our data illustrate that CD40L interacts with Mac-1 present on monocytes, and that CD40L functionally enhances monocyte adhesion and migration in vitro in a Mac-1-dependent fashion. Furthermore, we demonstrate functional involvement of Mac-1 in atherogenesis in vivo, because Mac-1 inhibition in LDLR Ϫ/Ϫ mice slowed lesion development and lesional macrophage accumulation. Growing evidence supports the concept that clustering of ␤2 integrins not only mediates cellular adhesion and migration, but also induces outside-in signaling, which results in altered gene expression. Thus, Mac-1 may participate in the expression of several proinflammatory cytokines including MIP-2, Ϫ/Ϫ mice not treated with anti-Mac-1 antibody. B, sCD40L induces Mac-1-dependent migration of inflammatory cells into the peritoneal cavity. Wild-type C57/BL mice were injected with sCD40L (75 g/mouse) 30 minutes after injection of PBS or anti-Mac-1 antibody (100 g/mouse). After 4 hours, inflammatory cells were harvested and quantified as described above (nϭ3 per group). C and D, Membrane-bound CD40L induces migration of inflammatory cells into the peritoneal cavity. Wild-type C57/BL6 mice were injected with mock-transfected fibroblasts (WT-fibroblasts) or fibroblasts that overexpressed CD40L (CD40L-fibroblasts, 5ϫ10 6 ) in the presence or absence of anti-Mac-1 antibody. After 4 hours (nՆ3 per group; C) and 72 hour (nՆ6 per group; D), inflammatory cells were harvested and quantified as described above. Data represent meanϮSEM. *PՅ0.05 compared with mice who received WT-fibroblasts. §PՅ0.05 compared with mice who received CD40L-fibroblasts without anti-Mac-1 pretreatment.
interleukin-1␤, interleukin-8, the procoagulant tissue factor, and in the activation of the proinflammatory transcription factor nuclear factor -B, which likely mediates the expression of the other factors. 50 -52 Interestingly, CD40L stimulation also elicits mediators induced by Mac-1 clustering on monocytes, and mediates many proinflammatory functions by nuclear factor -B activation. 2, 6 We show here that interaction of Mac-1 with CD40L enhances MPO release from monocytes. Recent work attributes proatherogenic functions to MPO, 53, 54 which suggests that CD40L not only may attract inflammatory cells via Mac-1, but also induces the expression of a variety of proinflammatory and prooxidant functions that promote atherogenesis.
Our present findings do not counter the multitude of reports that demonstrate CD40-dependent immunologic functions of CD40L. 55, 56 CD40L may very well exert its immunologic effects as costimulatory molecule in the T-celldependent humoral immune response via its classic receptor, yet its proinflammatory properties that promote chronic inflammatory diseases such as atherosclerosis may depend on interactions with other partners such as Mac-1. Indeed, a previous study suggested the existence of CD40-independent CD40L-induced functions. Mehlhop et al observed that bronchial hyperresponsiveness induced by Aspergillus inhalation requires CD40L but not CD40. They proposed a receptorindependent direct effect of CD40L on T lymphocytes or an interaction with an unknown other receptor on other leukocytes (eg, basophils). 57 Conversely, others have postulated the existence of alternative ligands for CD40. 58 Furthermore, other data show an interaction of CD40L with members of the integrin family. André et al demonstrated that CD40L stabilizes arterial thrombi by a ␣ IIb␤3 integrin-dependent mechanism, a function not modulated by the presence or absence of CD40. 14 Later, Prasad et al showed ␤ 3 integrin tyrosine phosphorylation induced by CD40L as an underlying mechanism. 15 Although this interaction with ␣ IIb␤3 may explain the prothrombotic functions of CD40L, the interactions with Mac-1 reported here may contribute more to the proinflammatory functions of CD40L on the plaque per se.
Our data from the present study do not establish that CD40L-Mac-1 interactions represent the exclusive mechanism of CD40L-induced inflammation. Mac-1 is rather specific for cells of the myeloid lineage, and CD40L exerts proinflammatory effects in a variety of cell types such as vascular smooth muscle and endothelial cells. 2, 6 CD40 as well as other receptors on these cell types may mediate some of CD40L-induced proinflammatory functions. CD40L binding to GP IIb/IIIa on platelets may also participate in atherogenesis. Similarly, some of the CD40-dependent immunologic functions of CD40L may contribute to atherosclerosis and many other inflammatory diseases. Our data highlight the pivotal role of CD40L in inflammation and inflammatory diseases such as atherosclerosis by uncovering a new mechanism of CD40L-induced inflammation. The present observations have important implications for both the mechanisms of inflammatory diseases as well as their therapeutic modulation.
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